查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1447737

急性眼痛市場評估：按藥物、病情、給藥途徑、分銷管道、最終用戶和地區劃分的機會和預測（2017-2031）

Acute Ocular Pain Market Assessment, By Drug, By Medical Condition, By Route of Administration, By Distribution Channel, By End-user, By Region, Opportunities and Forecast, 2017-2031F
出版日期: | 出版商: Market Xcel - Markets and Data | 英文 229 Pages | 商品交期: 3-5個工作天內

價格

全球急性眼痛市場規模預計將從 2023 年的 4.0177 億美元增長到 2031 年的 7.9645 億美元，2024-2031 年預測期間複合年增長率為 8.93%。

全球急性眼痛市場的發展是由人口老齡化加劇以及由此導致的眼部疾病患病率上升、醫療技術的進步以及對創新診斷工具和技術以加強眼科檢查過程的需求推動的.是由多種因素推動的，包括增加公共和私人投資以開發有效的治療方法。 此外，有利的監管框架、不斷增加的研發活動和合資企業也促進了市場的成長。

人口老化加劇

隨著人口老化的加劇，急性眼痛等眼部健康問題的盛行率正在迅速增加。 根據《2023 年世界社會報告》，全球 65 歲以上人口預計在未來 30 年內將翻一番，到 2050 年達到 16 億。 目前，老化人口估計佔世界人口的16%以上。 隨著年齡的增長，我們更容易患上乾眼症、青光眼、虹膜炎和感染等眼部疾病，這些疾病會導致不適和疼痛。 對抗這些與眼睛有關的疾病，最重要的是經常做眼科檢查，定期做眼科檢查，做好預防措施。 隨著老齡化社會的推進，該市場的研發活動不斷增加，以滿足不斷增長的人口的需求，全球急性眼痛市場的增長和需求預計將加速。

增加政府支持與措施

政府在控制和監測眼科疾病等醫療狀況方面發揮重要作用。 眼科檢查設備、治療藥物、眼科診所和其他眼保健設施是世界醫療保健系統的重要組成部分。 隨著急性眼痛等眼部問題的增加，對眼科檢查設備和安全有效的治療方案的需求持續成長。 為此，世界各國政府不斷實施政策和計劃，並採取舉措，促進創新和研究工作，開發有效的急性眼痛治療解決方案。

局部非類固醇抗發炎藥的需求不斷增加

在藥品領域中，外用非類固醇抗發炎藥物越來越受歡迎，並且預計將以更快的速度成長。 外用非類固醇抗發炎藥物受到許多公司和醫療保健專業人員的青睞，因為與其他藥物方法相比，它們安全有效。 由於需求不斷增長，多家領先公司正在其產品組合中引入這些產品。

本報告調查了全球急性眼痛市場，提供了市場定義和概述、市場規模趨勢和預測、各個細分市場和地區的詳細分析、行業結構以及影響市場成長的因素。我們編制分析、案例研究、競爭景觀、主要公司簡介等等。

目錄

第1章研究方法

第 2 章專案範圍與定義

第 3 章執行摘要

第4章全球急性眼痛市場展望

  • 市場規模/預測
  • 透過藥物
    • 外用非類固醇抗發炎藥
    • 局部循環麻痺
    • 口服止痛藥
    • 皮質類固醇
    • 免疫調節劑
  • 按症狀
    • 角膜擦傷
    • 青光眼
    • 結膜炎
    • 虹膜炎
    • 其他
  • 依給藥途徑
    • 本地
    • 眼周
    • 眼內
    • 口頭
    • 其他
  • 按分銷管道
    • 醫院藥房
    • 網路藥局
    • 零售藥局
  • 按最終用戶
    • 醫院
    • 居家護理
    • 眼科診所
    • 其他
  • 按地區
    • 北美
    • 歐洲
    • 南美洲
    • 亞太地區
    • 中東/非洲
  • 各公司的市佔率

第5章全球急性眼痛市場展望：依地區

  • 北美
  • 歐洲
  • 南美洲
  • 亞太地區
  • 中東/非洲

第 6 章市場映射

  • 透過藥物
  • 按症狀
  • 依給藥途徑
  • 按分銷管道
  • 按最終用戶
  • 按地區

第7章宏觀環境與產業結構

  • 需求與供給分析
  • 匯入/匯出分析
  • 價值鏈分析
  • PESTEL 分析
  • 波特五力分析

第 8 章市場動態

  • 生長促進因素
  • 抑制生長的因素（問題/抑制因素）

第 9 章監理架構與創新

  • 臨床試驗
  • 專利情況
  • 監理機關的核准
  • 創新/新興技術

第10章主要公司狀況

  • 前 5 名市場領導者的競爭矩陣
  • 前 5 位市場領導者的市場收入分析
  • 併購/合資企業（如果適用）
  • SWOT 分析（主要公司）
  • 專利分析（如果適用）

第11章價格分析

第 12 章案例研究

第13章主要公司展望

  • Alcon Vision LLC
  • Bausch + Lomb Corporation
  • Sun Pharmaceutical Industries Ltd.
  • AbbVie Inc.
  • Ocular Therapeutix, Inc.
  • KALA BIO, Inc.
  • Formosa Pharmaceuticals
  • Vyluma, Inc.
  • Sylentis S.A.
  • Aldeyra Therapeutics, Inc.

第 14 章策略建議

第15章關於我們公司/免責聲明

Product Code: MX11144

Global acute ocular pain market is projected to witness a CAGR of 8.93% during the forecast period 2024-2031, growing from USD 401.77 million in 2023 to USD 796.45 million in 2031. Growth in the global acute ocular pain market is driven by various factors, such as increasing aging population that contributes to a higher prevalence of ocular conditions, technological advancements in medical industry, increased demand for innovative diagnostic tools and techniques to enhance eye screening process, and growing investments by public and private firms in developing efficient treatment options. Additionally, favorable regulatory frameworks, increased research and development activities, along with collaboration ventures also lead to the growth of the global acute ocular pain market.

The global acute ocular pain market is experiencing tremendous growth due to various key factors. One of the primary drivers is the increasing aging population. The aging population contributes significantly to the increasing prevalence of acute ocular pain. Elderly people are more susceptible to ocular conditions that can lead to pain and inflammation and require immediate treatment. Due to this, there is an increased demand for drugs and therapeutical solutions for acute ocular pain. Government initiatives and support, such as granting funds, to enhance research and development activities in this market and implementation of policies and programs to manage and monitor eye-related conditions are propelling the market growth. The presence of key market players, along with continuous technological advancements in the market, is further driving the demand for highly advanced eye-care solutions. Moreover, collaboration activities, such as mergers and acquisitions, distribution agreements and partnerships, along with new entrants in the market, are further accelerating the growth of the global acute ocular pain market.

For instance, Mantis Photonics AB, which is a start-up founded in the year 2021, aims to make eye screening accessible to all by providing highly efficient early diagnosis facilities for timely detection and treatment of eye health conditions such as acute ocular pain.

Increasing Geriatric Population

With the growing aging population, there has been a surge in the prevalence of eye health issues such as acute ocular pain. According to World Social Report 2023, the global population of individuals aged 65 years or older is projected to increase twofold in the next thirty years, reaching 1.6 billion by 2050. It is estimated that by this point, the geriatric population will make up over 16% of the world's population. As individuals age, they become more vulnerable to ocular conditions like dry eyes, glaucoma, iritis, and infections, which can lead to discomfort and pain. To combat these eye-related diseases, it is of utmost importance that frequent eye screening, regular eye checkups, and preventive measures should be followed by the global population. With the growing aging population, there has been increased research and development activities in this market to cater to the needs of this growing population, which is expected to accelerate growth and demand for the global acute ocular pain market.

Increased Governmental Support and Initiatives

Government plays a crucial role in managing and monitoring medical conditions such as eye-related diseases. Eye care facilities, such as eye screening devices, therapeutical solutions, and eye care clinics, are an essential part of the health care system worldwide. As the prevalence of eye health conditions, such as acute ocular pain, is increasing, the demand for eye evaluation devices and safe and efficient treatment options continues to grow. Due to this, governments from all over the world are consistently taking initiatives and implementing policies and programs to increase innovation and research activities in developing efficient therapeutical solutions for acute ocular pain. For instance, in May 2023, National Health Service (NHS) England announced the implementation of a new clinical guidance, which could reduce waiting times for eye care services for patients in England as well as provide improved and efficient eye care diagnosis and treatment facilities to the people. The government is allocating resources and funds to bring innovation and development in ophthalmic care. This support is expected to improve the quality of eye care treatment for patients, further boosting the global acute ocular pain market.

Increased Demand for Topical NSAIDs

Among the drug segment, topical NSAIDs are gaining popularity, due to which this segment is expected to grow at a faster pace in the global acute ocular pain market. Topical NSAIDs are safer and more effective as compared to other forms of drug administration, due to which they are preferred by most companies and healthcare professionals. As the demand is rising, several leading players are launching these products in their product portfolio. For instance, Vyluma, an ophthalmic care company that works to improve the treatment quality of eye-related diseases, announced that it is developing NVK032, which is a topical NSAID eye drop. This is currently under clinical trial and has been developed for the treatment of acute ocular pain. These latest launches and research and development activities by the leading players in this segment are expected to spur growth in the global acute ocular pain market.

Hospitals Hold a Major Share in the Market

Among the end-user segment, hospitals hold a significant share of the global acute ocular pain market. The increasing global aging population and the rising number of hospitals to cater to the demands of this growing aging population are the main reasons for the dominance of the segment in this market. Acute ocular pain is a common eye condition occurring in most of the elderly population, further requiring immediate eye care and treatment. This has accelerated the need to establish more highly equipped hospitals to provide the necessary treatment. Due to this, developed, as well as developing countries, are increasing the number of hospitals with proper diagnostics and treatment facilities. For instance, according to the American Hospital Association, in the year 2023, there were 6,129 hospitals in the United States and now, more hospitals are under construction. Compared to other healthcare settings, hospitals ranks top in adopting the latest technologies and having efficient products and resources, due to which, there is increased trust among the people to approach hospitals for sensitive health conditions such as eye care. As a result, hospitals hold a significant market share in this market.

Asia-Pacific is Expected to Grow

Asia-Pacific is expected to be the fastest growing region in the global acute ocular pain market. Rapidly increasing population, along with growing aging population, is the major factor leading to the growth of this region in the forecasted period. For instance, the Economic and Social Commission for Asia and the Pacific states that in the year 2023, around 697 million individuals aged 60 years or older were living in Asia-Pacific, accounting for approximately 60% of the global geriatric population. Currently, one out of every seven individuals in the region are 60 years or older, also by 2050, this ratio is expected to increase to one in four. As the aging population holds a significant share in this region, it is expected that more and more people are prone to getting affected by eye health issues such as acute ocular pain. This has led to an increase in demand for effective treatment options and medical facilities in this region, leading to the growth of acute ocular pain market in Asia-Pacific. Moreover, Asia-Pacific is an emerging market, due to which key market players are establishing manufacturing and distribution facilities in the region to expand their business, leading to further growth of the global acute ocular pain market.

Future Market Scenario (2024 - 2031F)

The global acute ocular pain market is expected to grow in the future, primarily due to the increasing elderly population that leads to increased probability of eye-related diseases. Increasing governmental initiatives, policies, and programs to promote eye health and develop efficient treatment options are expected to drive market expansion. Technological advancements, favorable regulatory frameworks, increased investments by public and private eye health product manufacturers, along with collaborative ventures are some of the factors leading to significant growth in this market. For instance, in August 2023, OKYO Pharma, which is a biopharmaceutical company, announced partnership with Tufts Medical Center to develop OK-101. This product is the company's latest investment to create a therapeutic drug for relieving ocular pain. These investments and innovative launches are further accelerating the growth of the global acute ocular pain market.

Key Players Landscape and Outlook

In the acute ocular pain market, several leading players are frequently undergoing strategic partnerships and distribution agreements, which plays a pivotal role in propelling the global acute ocular pain market's expansion. These partnership agreements empower pharmaceuticals and ophthalmic companies to gain informative insights regarding the latest trends in the market, access each other's resources, technologies, and invest in research and development activities to bring efficient and innovative treatment options that can provide maximum benefit to the patients. Distribution agreements enable companies to broaden their market presence at a global level. These collaborative initiatives promote innovation, expedite product development, and contribute to the enduring and tremendous growth of the global market. For instance, in August 2022, Alcon, which is a key player in the eye care products market, announced that it has acquired Aerie Pharmaceuticals, Inc., a pharmaceutical company that focuses on manufacturing and developing efficient ophthalmic therapies. This acquisition would help the company to broaden the company's product portfolio and expand its global reach.

Table of Contents

1.Research Methodology

2.Project Scope & Definitions

3.Executive Summary

4.Global Acute Ocular Pain Market Outlook, 2017-2031F

  • 4.1.Market Size & Forecast
    • 4.1.1.By Value
    • 4.1.2.By Volume
  • 4.2.By Drug
    • 4.2.1.Topical NSAIDs
      • 4.2.1.1.Ketorolac (Acular LS)
      • 4.2.1.2.Diclofenac Sodium (Voltaren)
      • 4.2.1.3.Bromfenac Sodium (Xibrom)
      • 4.2.1.4.Nepafenac (Ilevro)
    • 4.2.2.Topical Cycloplegic Agents
      • 4.2.2.1.Atropine
      • 4.2.2.2.Scopolamine
      • 4.2.2.3.Homatropine
      • 4.2.2.4.Cyclopentolate
    • 4.2.3.Oral Analgesics
      • 4.2.3.1.Paracetamol
      • 4.2.3.2.Ibuprofen
      • 4.2.3.3.Naproxen
    • 4.2.4.Corticosteroids
      • 4.2.4.1.Prednisolone
      • 4.2.4.2.Prednisone
      • 4.2.4.3.Fluocinolone Acetonide
    • 4.2.5.Immunomodulators
      • 4.2.5.1.Cyclosporine
      • 4.2.5.2.Tacrolimus
      • 4.2.5.3.Lifitegrast
  • 4.3.By Medical Condition
    • 4.3.1.Corneal Abrasion
    • 4.3.2.Glaucoma
    • 4.3.3.Conjunctivitis
    • 4.3.4.Iritis
    • 4.3.5.Others
  • 4.4.By Route of Administration
    • 4.4.1.Topical
    • 4.4.2.Periocular
    • 4.4.3.Intraocular
    • 4.4.4.Oral
    • 4.4.5.Others
  • 4.5.By Distribution Channel
    • 4.5.1.Hospital Pharmacy
    • 4.5.2.Online Pharmacy
    • 4.5.3.Retail Pharmacy
  • 4.6.By End-user
    • 4.6.1.Hospitals
    • 4.6.2.Homecare
    • 4.6.3.Ophthalmic Clinics
    • 4.6.4.Others
  • 4.7.By Region
    • 4.7.1.North America
    • 4.7.2.Europe
    • 4.7.3.Asia-Pacific
    • 4.7.4.South America
    • 4.7.5.Middle East and Africa
  • 4.8.By Company Market Share (%), 2023

5.Global Acute Ocular Pain Market Outlook, By Region, 2017-2031F

  • 5.1.North America*
    • 5.1.1.Market Size & Forecast
      • 5.1.1.1.By Value
      • 5.1.1.2.By Volume
    • 5.1.2.By Drug
      • 5.1.2.1.Topical NSAIDs
      • 5.1.2.1.1.Ketorolac (Acular LS)
      • 5.1.2.1.2.Diclofenac Sodium (Voltaren)
      • 5.1.2.1.3.Bromfenac Sodium (Xibrom)
      • 5.1.2.1.4.Nepafenac (Ilevro)
      • 5.1.2.2.Topical Cycloplegic Agents
      • 5.1.2.2.1.Atropine
      • 5.1.2.2.2.Scopolamine
      • 5.1.2.2.3.Homatropine
      • 5.1.2.2.4.Cyclopentolate
      • 5.1.2.3.Oral Analgesics
      • 5.1.2.3.1.Paracetamol
      • 5.1.2.3.2.Ibuprofen
      • 5.1.2.3.3.Naproxen
      • 5.1.2.4.Corticosteroids
      • 5.1.2.4.1.Prednisolone
      • 5.1.2.4.2.Prednisone
      • 5.1.2.4.3.Fluocinolone Acetonide
      • 5.1.2.5.Immunomodulators
      • 5.1.2.5.1.Cyclosporine
      • 5.1.2.5.2.Tacrolimus
      • 5.1.2.5.3.Lifitegrast
    • 5.1.3.By Medical Condition
      • 5.1.3.1.Corneal Abrasion
      • 5.1.3.2.Glaucoma
      • 5.1.3.3.Conjunctivitis
      • 5.1.3.4.Iritis
      • 5.1.3.5.Others
    • 5.1.4.By Route of Administration
      • 5.1.4.1.Topical
      • 5.1.4.2.Periocular
      • 5.1.4.3.Intraocular
      • 5.1.4.4.Oral
      • 5.1.4.5.Others
    • 5.1.5.By Distribution Channel
      • 5.1.5.1.Hospital Pharmacy
      • 5.1.5.2.Online Pharmacy
      • 5.1.5.3.Retail Pharmacy
    • 5.1.6.By End-user
      • 5.1.6.1.Hospitals
      • 5.1.6.2.Homecare
      • 5.1.6.3.Ophthalmic Clinics
      • 5.1.6.4.Others
    • 5.1.7.United States*
      • 5.1.7.1.Market Size & Forecast
      • 5.1.7.1.1.By Value
      • 5.1.7.1.2.By Volume
      • 5.1.7.2.By Drug
      • 5.1.7.2.1.Topical NSAIDs
      • 5.1.7.2.1.1.Ketorolac (Acular LS)
      • 5.1.7.2.1.2.Diclofenac Sodium (Voltaren)
      • 5.1.7.2.1.3.Bromfenac Sodium (Xibrom)
      • 5.1.7.2.1.4.Nepafenac (Ilevro)
      • 5.1.7.2.2.Topical Cycloplegic Agents
      • 5.1.7.2.2.1.Atropine
      • 5.1.7.2.2.2.Scopolamine
      • 5.1.7.2.2.3.Homatropine
      • 5.1.7.2.2.4.Cyclopentolate
      • 5.1.7.2.3.Oral Analgesics
      • 5.1.7.2.3.1.Paracetamol
      • 5.1.7.2.3.2.Ibuprofen
      • 5.1.7.2.3.3.Naproxen
      • 5.1.7.2.4.Corticosteroids
      • 5.1.7.2.4.1.Prednisolone
      • 5.1.7.2.4.2.Prednisone
      • 5.1.7.2.4.3.Fluocinolone Acetonide
      • 5.1.7.2.5.Immunomodulators
      • 5.1.7.2.5.1.Cyclosporine
      • 5.1.7.2.5.2.Tacrolimus
      • 5.1.7.2.5.3.Lifitegrast
      • 5.1.7.3.By Medical Condition
      • 5.1.7.3.1.Corneal Abrasion
      • 5.1.7.3.2.Glaucoma
      • 5.1.7.3.3.Conjunctivitis
      • 5.1.7.3.4.Iritis
      • 5.1.7.3.5.Others
      • 5.1.7.4.By Route of Administration
      • 5.1.7.4.1.Topical
      • 5.1.7.4.2.Periocular
      • 5.1.7.4.3.Intraocular
      • 5.1.7.4.4.Oral
      • 5.1.7.4.5.Others
      • 5.1.7.5.By Distribution Channel
      • 5.1.7.5.1.Hospital Pharmacy
      • 5.1.7.5.2.Online Pharmacy
      • 5.1.7.5.3.Retail Pharmacy
      • 5.1.7.6.By End-user
      • 5.1.7.6.1.Hospitals
      • 5.1.7.6.2.Homecare
      • 5.1.7.6.3.Ophthalmic Clinics
      • 5.1.7.6.4.Others
    • 5.1.8.Canada
    • 5.1.9.Mexico

All segments will be provided for all regions and countries covered

  • 5.2.Europe
    • 5.2.1.Germany
    • 5.2.2.France
    • 5.2.3.Italy
    • 5.2.4.United Kingdom
    • 5.2.5.Russia
    • 5.2.6.Netherlands
    • 5.2.7.Spain
    • 5.2.8.Turkey
    • 5.2.9.Poland
  • 5.3.Asia-Pacific
    • 5.3.1.India
    • 5.3.2.China
    • 5.3.3.Japan
    • 5.3.4.Australia
    • 5.3.5.Vietnam
    • 5.3.6.South Korea
    • 5.3.7.Indonesia
    • 5.3.8.Philippines
  • 5.4.South America
    • 5.4.1.Brazil
    • 5.4.2.Argentina
  • 5.5.Middle East & Africa
    • 5.5.1.Saudi Arabia
    • 5.5.2.UAE
    • 5.5.3.South Africa

6.Market Mapping, 2023

  • 6.1.By Drug
  • 6.2.By Medical Condition
  • 6.3.By Route of Administration
  • 6.4.By Distribution Channel
  • 6.5.By End-user
  • 6.6.By Region

7.Macro Environment and Industry Structure

  • 7.1.Demand Supply Analysis
  • 7.2.Import Export Analysis
  • 7.3.Value Chain Analysis
  • 7.4.PESTEL Analysis
    • 7.4.1.Political Factors
    • 7.4.2.Economic System
    • 7.4.3.Social Implications
    • 7.4.4.Technological Advancements
    • 7.4.5.Environmental Impacts
    • 7.4.6.Legal Compliances and Regulatory Policies (Statutory Bodies Included)
  • 7.5.Porter's Five Forces Analysis
    • 7.5.1.Supplier Power
    • 7.5.2.Buyer Power
    • 7.5.3.Substitution Threat
    • 7.5.4.Threat from New Entrant
    • 7.5.5.Competitive Rivalry

8.Market Dynamics

  • 8.1.Growth Drivers
  • 8.2.Growth Inhibitors (Challenges and Restraints)

9.Regulatory Framework and Innovation

  • 9.1.Clinical Trials
  • 9.2.Patent Landscape
  • 9.3.Regulatory Approvals
  • 9.4.Innovations/Emerging Technologies

10.Key Players Landscape

  • 10.1.Competition Matrix of Top Five Market Leaders
  • 10.2.Market Revenue Analysis of Top Five Market Leaders (in %, 2023)
  • 10.3.Mergers and Acquisitions/Joint Ventures (If Applicable)
  • 10.4.SWOT Analysis (For Five Market Players)
  • 10.5.Patent Analysis (If Applicable)

11.Pricing Analysis

12.Case Studies

13.Key Players Outlook

  • 13.1.Alcon Vision LLC
    • 13.1.1.Company Details
    • 13.1.2.Key Management Personnel
    • 13.1.3.Products & Services
    • 13.1.4.Financials (As reported)
    • 13.1.5.Key Market Focus & Geographical Presence
    • 13.1.6.Recent Developments
  • 13.2.Bausch + Lomb Corporation
  • 13.3.Sun Pharmaceutical Industries Ltd.
  • 13.4.AbbVie Inc.
  • 13.5.Ocular Therapeutix, Inc.
  • 13.6.KALA BIO, Inc.
  • 13.7.Formosa Pharmaceuticals
  • 13.8.Vyluma, Inc.
  • 13.9.Sylentis S.A.
  • 13.10.Aldeyra Therapeutics, Inc.

Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work.

14.Strategic Recommendations

15.About Us & Disclaimer

List of Tables

  • Table 1. Pricing Analysis of Products from Key Players
  • Table 2. Competition Matrix of Top 5 Market Leaders
  • Table 3. Mergers & Acquisitions/ Joint Ventures (If Applicable)
  • Table 4. About Us - Regions and Countries Where We Have Executed Client Projects

List of Figures

  • Figure 1.Global Acute Ocular Pain Market, By Value, In USD Million, 2017-2031F
  • Figure 2.Global Acute Ocular Pain Market, By Volume, In Million Units, 2017-2031F
  • Figure 3.Global Acute Ocular Pain Market Share (%), By Drug, 2017-2031F
  • Figure 4.Global Acute Ocular Pain Market Share (%), By Medical Condition, 2017-2031F
  • Figure 5.Global Acute Ocular Pain Market Share (%), By Route of Administration, 2017-2031F
  • Figure 6.Global Acute Ocular Pain Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 7.Global Acute Ocular Pain Market Share (%), By End-user, 2017-2031F
  • Figure 8.Global Acute Ocular Pain Market Share (%), By Region, 2017-2031F
  • Figure 9.North America Acute Ocular Pain Market, By Value, In USD Million, 2017-2031F
  • Figure 10.North America Acute Ocular Pain Market, By Volume, In Million Units, 2017-2031F
  • Figure 11.North America Acute Ocular Pain Market Share (%), By Drug, 2017-2031F
  • Figure 12.North America Acute Ocular Pain Market Share (%), By Medical Condition, 2017-2031F
  • Figure 13.North America Acute Ocular Pain Market Share (%), By Route of Administration, 2017-2031F
  • Figure 14.North America Acute Ocular Pain Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 15.North America Acute Ocular Pain Market Share (%), By End-user, 2017-2031F
  • Figure 16.North America Acute Ocular Pain Market Share (%), By Country, 2017-2031F
  • Figure 17.United States Acute Ocular Pain Market, By Value, In USD Million, 2017-2031F
  • Figure 18.United States Acute Ocular Pain Market, By Volume, In Million Units, 2017-2031F
  • Figure 19.United States Acute Ocular Pain Market Share (%), By Drug, 2017-2031F
  • Figure 20.United States Acute Ocular Pain Market Share (%), By Medical Condition, 2017-2031F
  • Figure 21.United States Acute Ocular Pain Market Share (%), By Route of Administration, 2017-2031F
  • Figure 22.United States Acute Ocular Pain Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 23.United States Acute Ocular Pain Market Share (%), By End-user, 2017-2031F
  • Figure 24.Canada Acute Ocular Pain Market, By Value, In USD Million, 2017-2031F
  • Figure 25.Canada Acute Ocular Pain Market, By Volume, In Million Units, 2017-2031F
  • Figure 26.Canada Acute Ocular Pain Market Share (%), By Drug, 2017-2031F
  • Figure 27.Canada Acute Ocular Pain Market Share (%), By Medical Condition, 2017-2031F
  • Figure 28.Canada Acute Ocular Pain Market Share (%), By Route of Administration, 2017-2031F
  • Figure 29.Canada Acute Ocular Pain Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 30.Canada Acute Ocular Pain Market Share (%), By End-user, 2017-2031F
  • Figure 31.Mexico Acute Ocular Pain Market, By Value, In USD Million, 2017-2031F
  • Figure 32.Mexico Acute Ocular Pain Market, By Volume, In Million Units, 2017-2031F
  • Figure 33.Mexico Acute Ocular Pain Market Share (%), By Drug, 2017-2031F
  • Figure 34.Mexico Acute Ocular Pain Market Share (%), By Medical Condition, 2017-2031F
  • Figure 35.Mexico Acute Ocular Pain Market Share (%), By Route of Administration, 2017-2031F
  • Figure 36.Mexico Acute Ocular Pain Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 37.Mexico Acute Ocular Pain Market Share (%), By End-user, 2017-2031F
  • Figure 38.Europe Acute Ocular Pain Market, By Value, In USD Million, 2017-2031F
  • Figure 39.Europe Acute Ocular Pain Market, By Volume, In Million Units, 2017-2031F
  • Figure 40.Europe Acute Ocular Pain Market Share (%), By Drug, 2017-2031F
  • Figure 41.Europe Acute Ocular Pain Market Share (%), By Medical Condition, 2017-2031F
  • Figure 42.Europe Acute Ocular Pain Market Share (%), By Route of Administration, 2017-2031F
  • Figure 43.Europe Acute Ocular Pain Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 44.Europe Acute Ocular Pain Market Share (%), By Country, 2017-2031F
  • Figure 45.Europe Acute Ocular Pain Market Share (%), By End-user, 2017-2031F
  • Figure 46.Germany Acute Ocular Pain Market, By Value, In USD Million, 2017-2031F
  • Figure 47.Germany Acute Ocular Pain Market, By Volume, In Million Units, 2017-2031F
  • Figure 48.Germany Acute Ocular Pain Market Share (%), By Drug, 2017-2031F
  • Figure 49.Germany Acute Ocular Pain Market Share (%), By Medical Condition, 2017-2031F
  • Figure 50.Germany Acute Ocular Pain Market Share (%), By Route of Administration, 2017-2031F
  • Figure 51.Germany Acute Ocular Pain Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 52.Germany Acute Ocular Pain Market Share (%), By End-user, 2017-2031F
  • Figure 53.France Acute Ocular Pain Market, By Value, In USD Million, 2017-2031F
  • Figure 54.France Acute Ocular Pain Market, By Volume, In Million Units, 2017-2031F
  • Figure 55.France Acute Ocular Pain Market Share (%), By Drug, 2017-2031F
  • Figure 56.France Acute Ocular Pain Market Share (%), By Medical Condition, 2017-2031F
  • Figure 57.France Acute Ocular Pain Market Share (%), By Route of Administration, 2017-2031F
  • Figure 58.France Acute Ocular Pain Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 59.France Acute Ocular Pain Market Share (%), By End-user, 2017-2031F
  • Figure 60.Italy Acute Ocular Pain Market, By Value, In USD Million, 2017-2031F
  • Figure 61.Italy Acute Ocular Pain Market, By Volume, In Million Units, 2017-2031F
  • Figure 62.Italy Acute Ocular Pain Market Share (%), By Drug, 2017-2031F
  • Figure 63.Italy Acute Ocular Pain Market Share (%), By Medical Condition, 2017-2031F
  • Figure 64.Italy Acute Ocular Pain Market Share (%), By Route of Administration, 2017-2031F
  • Figure 65.Italy Acute Ocular Pain Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 66.Italy Acute Ocular Pain Market Share (%), By End-user, 2017-2031F
  • Figure 67.United Kingdom Acute Ocular Pain Market, By Value, In USD Million, 2017-2031F
  • Figure 68.United Kingdom Acute Ocular Pain Market, By Volume, In Million Units, 2017-2031F
  • Figure 69.United Kingdom Acute Ocular Pain Market Share (%), By Drug, 2017-2031F
  • Figure 70.United Kingdom Acute Ocular Pain Market Share (%), By Medical Condition, 2017-2031F
  • Figure 71.United Kingdom Acute Ocular Pain Market Share (%), By Route of Administration, 2017-2031F
  • Figure 72.United Kingdom Acute Ocular Pain Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 73.United Kingdom Acute Ocular Pain Market Share (%), By End-user, 2017-2031F
  • Figure 74.Russia Acute Ocular Pain Market, By Value, In USD Million, 2017-2031F
  • Figure 75.Russia Acute Ocular Pain Market, By Volume, In Million Units, 2017-2031F
  • Figure 76.Russia Acute Ocular Pain Market Share (%), By Drug, 2017-2031F
  • Figure 77.Russia Acute Ocular Pain Market Share (%), By Medical Condition, 2017-2031F
  • Figure 78.Russia Acute Ocular Pain Market Share (%), By Route of Administration, 2017-2031F
  • Figure 79.Russia Acute Ocular Pain Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 80.Russia Acute Ocular Pain Market Share (%), By End-user, 2017-2031F
  • Figure 81.Netherlands Acute Ocular Pain Market, By Value, In USD Million, 2017-2031F
  • Figure 82.Netherlands Acute Ocular Pain Market, By Volume, In Million Units, 2017-2031F
  • Figure 83.Netherlands Acute Ocular Pain Market Share (%), By Drug, 2017-2031F
  • Figure 84.Netherlands Acute Ocular Pain Market Share (%), By Medical Condition, 2017-2031F
  • Figure 85.Netherlands Acute Ocular Pain Market Share (%), By Route of Administration, 2017-2031F
  • Figure 86.Netherlands Acute Ocular Pain Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 87.Netherlands Acute Ocular Pain Market Share (%), By End-user, 2017-2031F
  • Figure 88.Spain Acute Ocular Pain Market, By Value, In USD Million, 2017-2031F
  • Figure 89.Spain Acute Ocular Pain Market, By Volume, In Million Units, 2017-2031F
  • Figure 90.Spain Acute Ocular Pain Market Share (%), By Drug, 2017-2031F
  • Figure 91.Spain Acute Ocular Pain Market Share (%), By Medical Condition, 2017-2031F
  • Figure 92.Spain Acute Ocular Pain Market Share (%), By Route of Administration, 2017-2031F
  • Figure 93.Spain Acute Ocular Pain Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 94.Spain Acute Ocular Pain Market Share (%), By End-user, 2017-2031F
  • Figure 95.Turkey Acute Ocular Pain Market, By Value, In USD Million, 2017-2031F
  • Figure 96.Turkey Acute Ocular Pain Market, By Volume, In Million Units, 2017-2031F
  • Figure 97.Turkey Acute Ocular Pain Market Share (%), By Drug, 2017-2031F
  • Figure 98.Turkey Acute Ocular Pain Market Share (%), By Medical Condition, 2017-2031F
  • Figure 99.Turkey Acute Ocular Pain Market Share (%), By Route of Administration, 2017-2031F
  • Figure 100.Turkey Acute Ocular Pain Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 101.Turkey Acute Ocular Pain Market Share (%), By End-user, 2017-2031F
  • Figure 102.Poland Acute Ocular Pain Market, By Value, In USD Million, 2017-2031F
  • Figure 103.Poland Acute Ocular Pain Market, By Volume, In Million Units, 2017-2031F
  • Figure 104.Poland Acute Ocular Pain Market Share (%), By Drug, 2017-2031F
  • Figure 105.Poland Acute Ocular Pain Market Share (%), By Medical Condition, 2017-2031F
  • Figure 106.Poland Acute Ocular Pain Market Share (%), By Route of Administration, 2017-2031F
  • Figure 107.Poland Acute Ocular Pain Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 108.Poland Acute Ocular Pain Market Share (%), By End-user, 2017-2031F
  • Figure 109.South America Acute Ocular Pain Market, By Value, In USD Million, 2017-2031F
  • Figure 110.South America Acute Ocular Pain Market, By Volume, In Million Units, 2017-2031F
  • Figure 111.South America Acute Ocular Pain Market Share (%), By Drug, 2017-2031F
  • Figure 112.South America Acute Ocular Pain Market Share (%), By Medical Condition, 2017-2031F
  • Figure 113.South America Acute Ocular Pain Market Share (%), By Route of Administration, 2017-2031F
  • Figure 114.South America Acute Ocular Pain Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 115.South America Acute Ocular Pain Market Share (%), By End-user, 2017-2031F
  • Figure 116.South America Acute Ocular Pain Market Share (%), By Country, 2017-2031F
  • Figure 117.Brazil Acute Ocular Pain Market, By Value, In USD Million, 2017-2031F
  • Figure 118.Brazil Acute Ocular Pain Market, By Volume, In Million Units, 2017-2031F
  • Figure 119.Brazil Acute Ocular Pain Market Share (%), By Drug, 2017-2031F
  • Figure 120.Brazil Acute Ocular Pain Market Share (%), By Medical Condition, 2017-2031F
  • Figure 121.Brazil Acute Ocular Pain Market Share (%), By Route of Administration, 2017-2031F
  • Figure 122.Brazil Acute Ocular Pain Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 123.Brazil Acute Ocular Pain Market Share (%), By End-user, 2017-2031F
  • Figure 124.Argentina Acute Ocular Pain Market, By Value, In USD Million, 2017-2031F
  • Figure 125.Argentina Acute Ocular Pain Market, By Volume, In Million Units, 2017-2031F
  • Figure 126.Argentina Acute Ocular Pain Market Share (%), By Drug, 2017-2031F
  • Figure 127.Argentina Acute Ocular Pain Market Share (%), By Medical Condition, 2017-2031F
  • Figure 128.Argentina Acute Ocular Pain Market Share (%), By Route of Administration, 2017-2031F
  • Figure 129.Argentina Acute Ocular Pain Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 130.Argentina Acute Ocular Pain Market Share (%), By End-user, 2017-2031F
  • Figure 131.Asia-Pacific Acute Ocular Pain Market, By Value, In USD Million, 2017-2031F
  • Figure 132.Asia-Pacific Acute Ocular Pain Market, By Volume, In Million Units, 2017-2031F
  • Figure 133.Asia-Pacific Acute Ocular Pain Market Share (%), By Drug, 2017-2031F
  • Figure 134.Asia-Pacific Acute Ocular Pain Market Share (%), By Medical Condition, 2017-2031F
  • Figure 135.Asia-Pacific Acute Ocular Pain Market Share (%), By Route of Administration, 2017-2031F
  • Figure 136.Asia-Pacific Acute Ocular Pain Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 137.Asia-Pacific Acute Ocular Pain Market Share (%), By End-user, 2017-2031F
  • Figure 138.Asia-Pacific Acute Ocular Pain Market Share (%), By Country, 2017-2031F
  • Figure 139.India Acute Ocular Pain Market, By Value, In USD Million, 2017-2031F
  • Figure 140.India Acute Ocular Pain Market, By Volume, In Million Units, 2017-2031F
  • Figure 141.India Acute Ocular Pain Market Share (%), By Drug, 2017-2031F
  • Figure 142.India Acute Ocular Pain Market Share (%), By Medical Condition, 2017-2031F
  • Figure 143.India Acute Ocular Pain Market Share (%), By Route of Administration, 2017-2031F
  • Figure 144.India Acute Ocular Pain Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 145.India Acute Ocular Pain Market Share (%), By End-user, 2017-2031F
  • Figure 146.China Acute Ocular Pain Market, By Value, In USD Million, 2017-2031F
  • Figure 147.China Acute Ocular Pain Market, By Volume, In Million Units, 2017-2031F
  • Figure 148.China Acute Ocular Pain Market Share (%), By Drug, 2017-2031F
  • Figure 149.China Acute Ocular Pain Market Share (%), By Medical Condition, 2017-2031F
  • Figure 150.China Acute Ocular Pain Market Share (%), By Route of Administration, 2017-2031F
  • Figure 151.China Acute Ocular Pain Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 152.China Acute Ocular Pain Market Share (%), By End-user, 2017-2031F
  • Figure 153.Japan Acute Ocular Pain Market, By Value, In USD Million, 2017-2031F
  • Figure 154.Japan Acute Ocular Pain Market, By Volume, In Million Units, 2017-2031F
  • Figure 155.Japan Acute Ocular Pain Market Share (%), By Drug, 2017-2031F
  • Figure 156.Japan Acute Ocular Pain Market Share (%), By Medical Condition, 2017-2031F
  • Figure 157.Japan Acute Ocular Pain Market Share (%), By Route of Administration, 2017-2031F
  • Figure 158.Japan Acute Ocular Pain Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 159.Japan Acute Ocular Pain Market Share (%), By End-user, 2017-2031F
  • Figure 160.Australia Acute Ocular Pain Market, By Value, In USD Million, 2017-2031F
  • Figure 161.Australia Acute Ocular Pain Market, By Volume, In Million Units, 2017-2031F
  • Figure 162.Australia Acute Ocular Pain Market Share (%), By Drug, 2017-2031F
  • Figure 163.Australia Acute Ocular Pain Market Share (%), By Medical Condition, 2017-2031F
  • Figure 164.Australia Acute Ocular Pain Market Share (%), By Route of Administration, 2017-2031F
  • Figure 165.Australia Acute Ocular Pain Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 166.Australia Acute Ocular Pain Market Share (%), By End-user, 2017-2031F
  • Figure 167.Vietnam Acute Ocular Pain Market, By Value, In USD Million, 2017-2031F
  • Figure 168.Vietnam Acute Ocular Pain Market, By Volume, In Million Units, 2017-2031F
  • Figure 169.Vietnam Acute Ocular Pain Market Share (%), By Drug, 2017-2031F
  • Figure 170.Vietnam Acute Ocular Pain Market Share (%), By Medical Condition, 2017-2031F
  • Figure 171.Vietnam Acute Ocular Pain Market Share (%), By Route of Administration, 2017-2031F
  • Figure 172.Vietnam Acute Ocular Pain Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 173.Vietnam Acute Ocular Pain Market Share (%), By End-user, 2017-2031F
  • Figure 174.South Korea Acute Ocular Pain Market, By Value, In USD Million, 2017-2031F
  • Figure 175.South Korea Acute Ocular Pain Market, By Volume, In Million Units, 2017-2031F
  • Figure 176.South Korea Acute Ocular Pain Market Share (%), By Drug, 2017-2031F
  • Figure 177.South Korea Acute Ocular Pain Market Share (%), By Medical Condition, 2017-2031F
  • Figure 178.South Korea Acute Ocular Pain Market Share (%), By Route of Administration, 2017-2031F
  • Figure 179.South Korea Acute Ocular Pain Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 180.South Korea Acute Ocular Pain Market Share (%), By End-user, 2017-2031F
  • Figure 181.Indonesia Acute Ocular Pain Market, By Value, In USD Million, 2017-2031F
  • Figure 182.Indonesia Acute Ocular Pain Market, By Volume, In Million Units, 2017-2031F
  • Figure 183.Indonesia Acute Ocular Pain Market Share (%), By Drug, 2017-2031F
  • Figure 184.Indonesia Acute Ocular Pain Market Share (%), By Medical Condition, 2017-2031F
  • Figure 185.Indonesia Acute Ocular Pain Market Share (%), By Route of Administration, 2017-2031F
  • Figure 186.Indonesia Acute Ocular Pain Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 187.Indonesia Acute Ocular Pain Market Share (%), By End-user, 2017-2031F
  • Figure 188.Philippines Acute Ocular Pain Market, By Value, In USD Million, 2017-2031F
  • Figure 189.Philippines Acute Ocular Pain Market, By Volume, In Million Units, 2017-2031F
  • Figure 190.Philippines Acute Ocular Pain Market Share (%), By Drug, 2017-2031F
  • Figure 191.Philippines Acute Ocular Pain Market Share (%), By Medical Condition, 2017-2031F
  • Figure 192.Philippines Acute Ocular Pain Market Share (%), By Route of Administration, 2017-2031F
  • Figure 193.Philippines Acute Ocular Pain Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 194.Philippines Acute Ocular Pain Market Share (%), By End-user, 2017-2031F
  • Figure 195.Middle East & Africa Acute Ocular Pain Market, By Value, In USD Million, 2017-2031F
  • Figure 196.Middle East & Africa Acute Ocular Pain Market, By Volume, In Million Units, 2017-2031F
  • Figure 197.Middle East & Africa Acute Ocular Pain Market Share (%), By Drug, 2017-2031F
  • Figure 198.Middle East & Africa Acute Ocular Pain Market Share (%), By Medical Condition, 2017-2031F
  • Figure 199.Middle East & Africa Acute Ocular Pain Market Share (%), By Route of Administration, 2017-2031F
  • Figure 200.Middle East & Africa Acute Ocular Pain Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 201.Middle East & Africa Acute Ocular Pain Market Share (%), By End-user, 2017-2031F
  • Figure 202.Middle East & Africa Acute Ocular Pain Market Share (%), By Country, 2017-2031F
  • Figure 203.Saudi Arabia Acute Ocular Pain Market, By Value, In USD Million, 2017-2031F
  • Figure 204.Saudi Arabia Acute Ocular Pain Market, By Volume, In Million Units, 2017-2031F
  • Figure 205.Saudi Arabia Acute Ocular Pain Market Share (%), By Drug, 2017-2031F
  • Figure 206.Saudi Arabia Acute Ocular Pain Market Share (%), By Medical Condition, 2017-2031F
  • Figure 207.Saudi Arabia Acute Ocular Pain Market Share (%), By Route of Administration, 2017-2031F
  • Figure 208.Saudi Arabia Acute Ocular Pain Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 209.Saudi Arabia Acute Ocular Pain Market Share (%), By End-user, 2017-2031F
  • Figure 210.UAE Acute Ocular Pain Market, By Value, In USD Million, 2017-2031F
  • Figure 211.UAE Acute Ocular Pain Market, By Volume, In Million Units, 2017-2031F
  • Figure 212.UAE Acute Ocular Pain Market Share (%), By Drug, 2017-2031F
  • Figure 213.UAE Acute Ocular Pain Market Share (%), By Medical Condition, 2017-2031F
  • Figure 214.UAE Acute Ocular Pain Market Share (%), By Route of Administration, 2017-2031F
  • Figure 215.UAE Acute Ocular Pain Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 216.UAE Acute Ocular Pain Market Share (%), By End-user, 2017-2031F
  • Figure 217.South Africa Acute Ocular Pain Market, By Value, In USD Million, 2017-2031F
  • Figure 218.South Africa Acute Ocular Pain Market, By Volume, In Million Units, 2017-2031F
  • Figure 219.South Africa Acute Ocular Pain Market Share (%), By Drug, 2017-2031F
  • Figure 220.South Africa Acute Ocular Pain Market Share (%), By Medical Condition, 2017-2031F
  • Figure 221.South Africa Acute Ocular Pain Market Share (%), By Route of Administration, 2017-2031F
  • Figure 222.South Africa Acute Ocular Pain Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 223.South Africa Acute Ocular Pain Market Share (%), By End-user, 2017-2031F
  • Figure 224.By Drug Map-Market Size (USD Million) & Growth Rate (%), 2023
  • Figure 225.By Medical Condition Map-Market Size (USD Million) & Growth Rate (%), 2023
  • Figure 226.By Route of Administration Map-Market Size (USD Million) & Growth Rate (%), 2023
  • Figure 227.By Distribution Channel Map-Market Size (USD Million) & Growth Rate (%), 2023
  • Figure 228.By End-user Map-Market Size (USD Million) & Growth Rate (%), 2023
  • Figure 229.By Region Map-Market Size (USD Million) & Growth Rate (%), 2023